Hematopoietic stem cell transplantation using non-cryopreserved peripheral blood stem cells graft is effective in multiple myeloma and lymphoma

Naithani, Rahul; Dayal, Nitin; Pathak, Sangeeta; Rai, Reeta

doi:10.1038/s41409-018-0174-9

Cited by 17 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Six patients underwent autologous transplant despite not achieving the target cell dose (2 £ 10 6 CD34 cells/kg) in 2 days of apheresis. Similar to previous reports [10] all of them engrafted, although the platelet engraftment in these 6 patients was delayed. Table 2 shows a comparison of the data on engraftment from few studies using cryopreserved versus non-cryopreserved grafts.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant

Kulkarni

Devasia

Korula

et al. 2018

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Autologous transplantation is the standard of care for transplant-eligible patients with multiple myeloma. Toward making this treatment accessible in developing countries, there are significant challenges like resource constraints and access to cryopreservation facilities. We performed a retrospective analysis of patients with multiple myeloma who underwent autologous transplantation using granulocyte colony-stimulating factor (G-CSF)-mobilized non-cryopreserved grafts at our institution from January 1995 to December 2014. Peripheral blood stem cells (PBSCs) were harvested over 1 to 2 days after G-CSF mobilization. After apheresis, PBSCs were stored at 4°C in a blood bank refrigerator for up to 72 hours. During the study period, 224 patients with multiple myeloma underwent autologous transplantation using G-CSF-mobilized non-cryopreserved grafts. The number of days of stem cell harvest was 1 in 91 patients (40.6%) and 2 in 133 patients (59.4%). The median CD34 cell dose was 4.87 × 10/kg (range, 1.15 to 23.7). All patients except 1 engrafted. The median time to neutrophil engraftment was 12 days (range, 9 to 22). The median time to platelet engraftment was 17 days (range, 10 to 44). In a resource-limited setting, the use of G-CSF-mobilized non-cryopreserved grafts results in adequate engraftment for most patients with multiple myeloma undergoing autologous stem cell transplantation.

show abstract

Section: Discussionsupporting

confidence: 89%

“…Previous clinical studies have shown that autologous transplantation for myelomas and lymphomas is feasible without cryopreserving the graft [2][3][4]10,17,18]. Cryopreservation is necessary in certain scenarios wherein the transplant has to be delayed after stem cell harvest or cells have to be stored for 2 transplants [19].…”

Section: Discussionmentioning

confidence: 99%

Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant

Kulkarni

Devasia

Korula

et al. 2018

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

show abstract

“…Finally, a possible advantage of such approach is to avoid the consequences of dimethyl sulfoxide toxicity; nevertheless, the development of automatic washing methods led to significantly decreased adverse effects related to infusion without affecting stem cell counts or viability [ 49 ]. Several clinical studies have shown that autologous transplantation is feasible without cryopreserving the graft [ 45 , 46 , 49 , 50 , 51 , 52 , 53 ].…”

Section: Considerations With Stem Cell Mobilization and Harvestingmentioning

confidence: 99%

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?

Morè

Corvatta²,

Manieri

et al. 2022

Cells

View full text Add to dashboard Cite

The introduction of high-dose therapy in the 1990s as well as the development of drugs such as thalidomide, lenalidomide, and bortezomib in the 2000s led to an impressive improvement in outcome of patients with multiple myeloma (MM) eligible for autologous stem cell transplantation (ASCT). Clinical trials conducted in the first ten years of the twenty-first century established as standard therapy for these patients a therapeutic approach including induction, single or double ASCT, consolidation, and maintenance therapy. More recently, incorporating second-generation proteasome inhibitors carfilzomib and monoclonal antibody daratumumab into each phase of treatment significantly improved the efficacy of ASCT in terms of measurable residual disease (MRD) negativity, Progression Free Survival (PFS), and Overall Survival (OS). The availability of techniques such as multiparameter flow cytometry (MFC) and next-generation sequencing (NGS) for MRD assessment allowed the design of MRD-based response-adjusted trials that will define, in particular, the role of consolidation and maintenance therapies. In this review, we will provide an overview of the most recent evidence and the future prospects of ASCT in MM patients.

show abstract

“…Outcomes were comparable to those from conventional conditioning with cryopreserved stem cells in patients with multiple myeloma [31][32][33][34]. Two recent studies of noncryopreserved autografts from developing countries using post-HSCT G-CSF also indicate comparable engraftment rates to cryopreserved autografts [35,36].…”

Section: Performing Autologous Hsct Without Stem Cell Cryopreservationmentioning

confidence: 74%

Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations

Aljurf

Weisdorf

Hashmi

et al. 2019

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

A B S T R A C T The development of hematopoietic stem cell transplantation (HSCT) programs can face significant challenges in most developing countries because such endeavors must compete with other government health care priorities, including the delivery of basic services. Although this is may be a limiting factor, these countries should prioritize development of the needed expertise to offer state-of-the-art treatments, including transplantation, by providing financial, technological, legal, ethical, and other needed support. This would prove beneficial in providing successful programs customized to the needs of their population and potentially provide long-term cost savings by circumventing the need for their citizens to seek care abroad. The costs of establishing an HSCT program and the costs of the HSCT procedure itself can be substantial barriers in developing countries. In addition, socioeconomic factors intrinsic to specific countries can influence access to HSCT, patient eligibility for HSCT, and timely utilization of HSCT center capabilities. This report describes recommendations from the Worldwide Network for Blood and Marrow Transplantation for establishing HSCT programs, with a specific focus on developing countries, and identifies challenges and opportunities for providing this specialized procedure in resource-constrained settings.

show abstract

Hematopoietic stem cell transplantation using non-cryopreserved peripheral blood stem cells graft is effective in multiple myeloma and lymphoma

Cited by 17 publications

References 11 publications

Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant

Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?

Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations

Contact Info

Product

Resources

About